Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 2.25p 2.00p 2.50p 2.25p 2.25p 2.25p 47,691.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.4 -0.3 -0.1 - 4.58

Feedback (FDBK) Latest News

More Feedback News
Feedback Takeover Rumours

Feedback (FDBK) Share Charts

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart

Intraday Feedback Chart

Intraday Feedback Chart

Feedback (FDBK) Discussions and Chat

Feedback (FDBK) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Feedback trades in real-time

Feedback (FDBK) Top Chat Posts

DateSubject
10/12/2016
08:20
Feedback Daily Update: Feedback Plc is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 2.25p.
Feedback Plc has a 4 week average price of 1.94p and a 12 week average price of 1.85p.
The 1 year high share price is 2.53p while the 1 year low share price is currently 0.68p.
There are currently 203,673,857 shares in issue and the average daily traded volume is 669,361 shares. The market capitalisation of Feedback Plc is £4,582,661.78.
07/10/2015
20:56
lr2: Feedback PLC, Don’t You Hate the Small Profit-Takers? Http://www.branduk.net/malcolm-stacey-of-shareprophets-feedback-plc-dont-you-hate-the-small-profit-takers/ Hello Share Bunnies. There was some interesting share movements after all the good news came out for Feedback (FDBK), the minnow capitalised at a mere £5 million. This firm which makes software to help in assessing cancers and other serious illnesses has been recording some big progress. The latest news to come in was that the National Health Service’s research arm has produced ‘an alert’ to the affect that this company is worth looking at. The share price put on 15%. It kept that level for most of the morning. Then the price began stepping up. There were small twitches until the golden share reached nearly a 50% rise on the day. This put Feedback at the top of the overall winners board. But not for long. The zenith proved to be a spike and the share inched down again to end the day at just 15% up. I checked the number of buys and sells throughout the day, and at no point did purchases exceed the sales. This rise and fall pattern is so common for penny shares these days. And I think we all know what’s going on.There is a large army out there who will take a profit, no matter what the great future might lie in store for the company. Feedback may not yet have recorded a recent profit, but it already nets £300,000 every 6 months by way of royalties and as their software is so desirable to find and treat serious cancers, I cannot see it failing to be a tasty go-er in the near future. Yet, so many holding the share are willing to take a short term profit. And they do that even though the spread is, as I look now, 20%. I think such short-term strategies are a mistake. They won’t realise much cash, because I notice the parcels of shares sold were largely tiny, many under £300. This could be a multi-bagger. I’m not daft enough to say that’s certain, or even probable, but I’m buying the shares and staying in for a few months at least. But what the heck? They say it’s never wrong to take a profit, and that does take a bit of arguing against. But personally I prefer a big profit to a small one. Time now for sampling duty – at the Punter’s Return.
06/10/2015
09:16
lr2: Thanks Blueball. I posted the NHS alert on here last Friday night (post #865) and nobody seemed to register the importance of it other than Britstox. Just as well Feedback got around to announcing the news today as my post had no effect on the share price. :)
05/6/2015
08:05
the stigologist: the ultra small round that fraudy took part in was simply designed to pump the share price i suspect
04/6/2015
12:13
sja123: Might be worth bearing in mind that the last time the company was requested to put out an RNS stating there was "no known reason for share price movement", they went on to make three or four further announcements in a couple of weeks, including deals in Korea, Brisbane, Texas and with Oxford Stone.... Just saying....it doesn't necessarily mean a jot.... and something is driving the volume here today IMO.... We'll see...but I'm quite happy to hold with what is already out there....
15/5/2015
12:33
norbert colon: Stig/21. The good thing about these BBs is the fact that they are an open forum for investors, traders and in fact anyone to comment on a particular share / company and generally it's great to get the mixed views of all involved. All I would add re: some of the comments in this board from yourselves is that: 1) the RNS re: share price movement has to be read in the context that any RNS that does not specify contract values and relate them to forecasts for the business are just business as usual. All the recent announcement are business as usual in some respect as they are a function of the company trading and undertaking business; they are not YET material with respect to orders etc and hence I understand why they released that statement although I agree that given their very small mcap and early start-up stature, the flurry of positive news does seem ironic / coincidental. 2) Let's not call others on this board liars or delve to similar levels. Go short if you think FDBK is all hot air. Anyway, enjoy the weekend all and let's all hope for further news. Nobby
26/4/2015
11:31
lr2: Bayer Healthcare Pharmaceuticals, Inc. / Bayer Schering Pharma are sponsoring the following "Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX". HTTP://clinicaltrials.gov/ct2/show/study/NCT02425683#contacts This US based Colorectal Cancer study was posted up on the US Government National Institutes of Health site last Thursday (the same day as the share price movement RNS). It is still in the recruiting participants phase. What makes this particular study interesting, I reckon, is the following paragraph in the Detailed Description section. "In addition, evaluating the Texture (spatial variations in pixel intensity) in computed tomography (CT) scans might help predict the risk of recurrence. Therefore, CT disks will be sent to Imaging Endpoints Core Lab, Scottsdale, AZ, where the TexRAD platform (a software algorithm) will be used for analysis." This could be a significant breakthrough for FDA approval.
23/4/2015
11:50
blueball: Nothing to worry about share price off 5%. I like the bit when they say they are in discussions with potential customers nice touch.
23/4/2015
11:29
21trader: Who's going to buy their shares if they issue 2 bits of good news and then say no reason for the rise. It's only gone from 1.5p offer to 2.5p offer the whole idea of good news is to increase the share price. Now if it was 4p I could understand it but the price was not moving at the time of Rns and there was little action in the previous 2 hours.
19/4/2015
19:10
alicia1983: Before the kidney stone trial announcement, the share price was 1-1-5p. Since the collaboration with the Oxford Stone Group RNS was released, the share price has moved to 1.5-1.8. From the RNS: "In the UK, an estimated 85,000 patients attend hospital with kidney stones each year..........which patients will benefit from lithotripsy would help to streamline treatment pathways and better allow clinicians to advise patients in choosing the right option for them. Similarly, using a non-invasive tool to better evaluate the composition of the stone facilitates personalised advice". But according to this: hxxp://parathyroid.com/kidney-stones.htm kidney stones are common throughout the world (between 3% and 5% of the population) so the numbers of potential beneficiaries (if it works) is quite appreciable. There is no guidance from the Company about what all this might mean, if anything, for potential revenues so shareholders have to form their own views - does anyone have any ideas?
16/4/2015
14:04
maxy26: This is hardly traded and directors own more than half the shares so it is not surprising that movements, when they occur are sharp and sudden. The technology is esoteric - if anyone can comprehend it - so if anything interesting is happening it is probably understandable only by the cognoscenti. The share price tells the story well enough probably....
Feedback share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20161211 02:20:33